Sierra Oncology, Inc.

( )
SRRA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 4.54%75.040.0%$1283.83m
NVAXNovavax, Inc. 5.42%109.97251.8%$925.58m
VXRTVaxart, Inc. 40.02%16.970.0%$812.62m
AMGNAmgen, Inc. 1.22%253.091.3%$689.90m
REGNRegeneron Pharmaceuticals, Inc. 4.12%641.232.5%$651.41m
GILDGilead Sciences, Inc. 0.67%77.191.0%$624.99m
BIIBBiogen, Inc. 1.72%281.271.4%$586.19m
VRTXVertex Pharmaceuticals, Inc. 3.16%293.831.9%$476.84m
ILMNIllumina, Inc. 1.93%376.253.5%$300.68m
BNTXBioNTech SE 7.84%83.880.0%$230.63m
BMRNBioMarin Pharmaceutical, Inc. 1.63%126.434.3%$212.09m
ALXNAlexion Pharmaceuticals, Inc. 1.44%108.572.0%$207.18m
SGENSeattle Genetics, Inc. 2.88%173.436.1%$188.36m
SRNESorrento Therapeutics, Inc. 2.85%7.941.8%$185.99m
IMMUImmunomedics, Inc. 1.70%40.6511.0%$172.19m

Company Profile

Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focuses on advancing targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada.